Age-related Clonal Haematopoiesis in an HIV Evaluation Cohort (ARCHIVE)
NCT04641013 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 446
Last updated 2020-11-23
Summary
The ARCHIVE study is an observational longitudinal cohort study of people with and without HIV who are over the age of 55. The duration of the study is planned for 10 years, with study visits every 1-2 years. The objectives of the study are to evaluate genomic and other factors associated with aging, stratified by HIV status.
Conditions
- HIV Infections
- Aging
Sponsors & Collaborators
-
Peter MacCallum Cancer Centre, Australia
collaborator OTHER -
Holdsworth House Medical Centre
collaborator UNKNOWN -
Prahran Market Clinic
collaborator UNKNOWN -
East Sydney Doctors
collaborator UNKNOWN -
RPA Sexual Health
collaborator UNKNOWN -
The Alfred
collaborator OTHER -
St Vincent's Hospital
collaborator OTHER -
Taylor Square Medical Practice
collaborator UNKNOWN -
Monash Health
collaborator OTHER -
Albion Street Clinic
collaborator UNKNOWN -
Kirby Institute
lead OTHER_GOV
Principal Investigators
-
Mark Polizzotto, MBBS, PhD · Kirby Institute, UNSW Sydney
-
Nila Dharan, MD · Kirby Institute, UNSW Sydney
-
Kathy Petoumenos, PhD · Kirby Institute, UNSW Sydney
Eligibility
- Sex
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-12-05
- Primary Completion
- 2019-04-17
- Completion
- 2027-12-04
Countries
- Australia
Study Locations
More Related Trials
-
Monitored Antiretroviral Pause in Chronic HIV-Infected Subjects With Long-Lasting Suppressed Viremia
NCT03198325 ·Status: COMPLETED ·Phase: NA
-
An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment
NCT00675844 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy
NCT01365065 ·Status: UNKNOWN ·Phase: PHASE2
-
Evolution of HIV Reservoir, Inflammation and Microbiota Footprint of PLWH Switching to Long-acting Injectable Treatment Compared to Patients on Oral Dual or Triple Anti-integrase-based Therapy
NCT05303337 ·Status: RECRUITING
-
Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease
NCT00775606 ·Status: TERMINATED ·Phase: PHASE4
-
Duration of Dual Antiretroviral Therapy in Virologically Suppressed People Living With HIV and Factors Associated With Switching to Tritherapy : a Real-life Cohort
NCT06107140 ·Status: COMPLETED
-
A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
NCT01272258 ·Status: WITHDRAWN ·Phase: PHASE2
-
Cohort of Patients Naive of Antiretroviral Treatment at Enrollment
NCT03137797 ·Status: COMPLETED
-
Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl
NCT00532168 ·Status: COMPLETED ·Phase: PHASE4
-
Effect on HIV Medications on EPC Cells
NCT03782142 ·Status: COMPLETED
-
PRO 140 for Human Immunodeficiency Virus Infection
NCT02257788 ·Status: WITHDRAWN ·Phase: PHASE2
-
First in Human Study of TLC-ART 101 (ACTU 2001)
NCT05850728 ·Status: COMPLETED ·Phase: PHASE1
-
RETRIeVE: ReversE TranscRiptase Inhibitor hiV Practice
NCT01154556 ·Status: COMPLETED
-
Dynamics of Drug Resistance-associated Mutations in HIV-1 DNA Reverse Transcriptase Clearance During Effective Antiretroviral Therapy
NCT04448158 ·Status: COMPLETED
-
An Observational Retrospective Database Analysis to Evaluate Raltegravir Based-regimens, Including NUC-sparing Regimens, in Aged HIV Patients.(RalAge)
NCT03579485 ·Status: UNKNOWN
-
The Use of Leukapheresis to Support HIV Pathogenesis Studies
NCT01161199 ·Status: RECRUITING
-
D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults
NCT01565850 ·Status: COMPLETED ·Phase: PHASE2
-
An Extension of Protocol PRO 140_CD01 Study
NCT02355184 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART
NCT01680094 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years
NCT02616783 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)
NCT03549689 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years
NCT03405935 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen
NCT02577042 ·Status: COMPLETED ·Phase: PHASE4
-
Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients.
NCT06061536 ·Status: COMPLETED ·Phase: PHASE2
-
Preliminary Study of Early, Primary HIV Infection in a High Risk Cohort
NCT00989144 ·Status: COMPLETED